A Single Arm Phase II Study of Cemiplimab-rwlc in Immunocompromised Patients with Unresectable Locally Recurrent and/or Metastatic Cutaneous Squamous Cell Carcinoma (CSCC)
The purpose of this research study is to determine how people with weakened immune systems and unresectable (cannot be removed by surgery) locally recurrent and/or metastatic cutaneous squamous cell carcinoma (CSCC) respond to study treatment with Cemiplimab.
Primary Objective: Determine the overall response rate of Cemiplimab-rwlc in immunocompromised patients with unresectable locally recurrent and/or metastatic CSCC. Secondary Objectives: to evaluate progression-free survival, to evaluate overall survival and to evaluate acute and late toxicities. Exploratory Objectives: To identify potential biomarkers related to response to Cemiplimab-rwlc in immunocompromised patients with unresectable locally recurrent and/or metastatic CSCC and to evaluate overall response rate of underlying CLL in the CLL subset.
Cemiplimab (); REGN2810 (Cemiplimab)
> Histologically confirmed diagnosis of invasive Cutaneous Squamous Cell Carcinoma (CSCC)
> Prior known allergy to Cemiplimab-rwlc
Back to top
Please call 1-888-663-3488 for support from a Moffitt representative. New Patients and Healthcare Professionals can submit an online form by selecting the appropriate button below. Existing patients can call 1-888-663-3488. Click here for a current list of insurances accepted at Moffitt.
NEW PATIENTS To request a new patient appointment, please fill out the online form or call 1-888-663-3488.
REFERRING PHYSICIANS Providers and medical staff can refer patients by submitting our online referral form.
Moffit now offers Virtual Visits for patients. If you are eligible for a virtual appointment, our scheduling team will discuss this option further with you.